[Intravenous immunoglobulin-induced thrombocytopenia in patient with chronic inflammatory demyelinating polyneuropathy].
chronic inflammatory demyelinating polyneuropathy
intravenous immunoglobulin therapy
side effect
thrombocytopenia
Journal
Rinsho shinkeigaku = Clinical neurology
ISSN: 1882-0654
Titre abrégé: Rinsho Shinkeigaku
Pays: Japan
ID NLM: 0417466
Informations de publication
Date de publication:
30 Jan 2020
30 Jan 2020
Historique:
pubmed:
20
12
2019
medline:
18
8
2020
entrez:
20
12
2019
Statut:
ppublish
Résumé
A 69-year-old man was admitted to our hospital because of dysesthesia in right palm and left upper limb, gait disturbance, and muscle weakness in both lower limbs. At the same time of neurological impairment appeared, he developed pemphigoid. Lumber MRI showed swelling of cauda equina nerve root. We diagnosed as chronic inflammatory demyelinating polyneuropathy based on an electrophysiological examination, and 2 courses of intravenous immunoglobulin therapy (IVIG) were initiated. After the treatments, symptoms improved immediately. However, thrombocytopenia was seen after each treatment which began on the second day of treatment start, reaching the lowest point from about 10 to 14 days, and improved naturally from 10 to 15 days after the end of IVIG. Difficulty in hemostasis was seen during dialysis due to thrombocytopenia. As a cause of thrombocytopenia, formation of IgG-platelet complexes could be considered, and the presence of multiple inflammatory diseases which activated Fcγ receptors play key roles could be a risk for IVIG related thrombocytopenia.
Identifiants
pubmed: 31852869
doi: 10.5692/clinicalneurol.cn-001331
doi:
Substances chimiques
Immunoglobulins, Intravenous
0
Types de publication
Case Reports
Journal Article
Langues
jpn
Sous-ensembles de citation
IM